Adlai Nortye Ltd. (NASDAQ:ANL) Sees Significant Growth in Short Interest

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 4,400 shares, an increase of 46.7% from the January 15th total of 3,000 shares. Based on an average daily volume of 13,300 shares, the days-to-cover ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Adlai Nortye in a research report on Monday, November 11th.

Adlai Nortye Price Performance

Shares of ANL stock opened at $2.25 on Friday. The firm has a fifty day moving average of $2.16 and a two-hundred day moving average of $2.36. Adlai Nortye has a 1-year low of $1.85 and a 1-year high of $17.48.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.